97 Results

People

  1. Lin
    Lin
  2. Matasar
    Matasar
  3. Levine
    Levine
  4. Zelenetz
    Zelenetz
  5. Mauro
    Mauro
  6. Van Den Brink
    Van Den Brink
  7. Tallman
    Tallman
  8. Horwitz
    Horwitz
  9. Lowe
    Lowe
  10. Rampal
    Rampal

Groups

  1. Center for Hematologic Malignancies (97)
  2. Department of Medicine (75)
  3. Hematologic Malignancies, Division of (74)
  4. Adult Leukemia (28)
  5. GSK Faculty (24)
  6. Lymphoma (23)
  7. Executive Committee, Center for Hematologic Malignancies (20)
  8. Pediatric Leukemia (18)
  9. Sloan Kettering Institute Faculty (14)
  10. Survivorship Research (12)
  1. "Center for Hematologic Malignancies"
  2. "S. Karger AG"
Formats
  1. Meeting Abstract (71)
  2. Journal Article (24)
  3. Review (2)
Groups
  1. Center for Hematologic Malignancies (97)
  2. Department of Medicine (75)
  3. Hematologic Malignancies, Division of (74)
  4. Adult Leukemia (28)
  5. GSK Faculty (24)
  6. Lymphoma (23)

More Groups

People
  1. Oscar Lin (16)
  2. Matthew Matasar (8)
  3. Andrew Zelenetz (7)
  4. Ross Levine (7)
  5. Marcel Van Den Brink (6)
  6. Michael Mauro (6)

More People

Years
  1. 2024 (1)
  2. 2023 (12)
  3. 2022 (10)
  4. 2021 (6)
  5. 2020 (10)
  6. 2019 (6)

More Years

Publications
  1. Oncology Research and Treatment (55)
  2. Acta Cytologica (15)
  3. Acta Haematologica (13)
  4. Onkologie (5)
  5. Cytogenetic and Genome Research (2)
  6. Cytogenetics and Cell Genetics (1)

More Publications

Publishers
  1. S. Karger AG (97)

Results (97)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessment of micronuclei frequency in the peripheral blood of adult and pediatric patients receiving fractionated total body irradiation
    Journal Article

    Kanagaraj, K.; Phillippi, M. A.; Narayan, P.; Szolc, B.; Perrier, J. R.; McLane, A.; Wolden, S. L.; Barker, C. A.; Wang, Q.; Amundson, S. A.; more...
    Cytogenetic and Genome Research (2024)

    Fulltext@MSK | Save
  • Primary overall survival (OS) analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Meeting Abstract

    Dreger, P.; Westin, J.; Oluwole, O.; Kersten, M. J.; Miklos, D.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Dietrich, S.; Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Fay, K.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies
    Meeting Abstract

    Raab, M. S.; Hanel, M.; Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Assessing the burden of adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Stilgenbauer, S.; Seymour, J. F.; Byrd, J. C.; Munir, T.; Ghia, P.; Kater, A. P.; Chanan-Khan, A.; Furman, R. R.; O'Brien, S. M.; Brown, J. R.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subgroup analyses of primary refractory vs early relapsed large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy
    Meeting Abstract

    Glass, B.; Nastoupil, L.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López-Guillermo, A.; Martínez-López, J.; Novak, U.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL): Updated results from a phase I/II study
    Meeting Abstract

    von Tresckow, B.; Budde, L. E.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M.; Gutierrez, N. C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Patient reported outcomes in triple class exposed, relapsed/refractory multiple myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): Idecabtagene Vicleucel (ide-cel) versus standard regimens
    Meeting Abstract

    Einsele, H.; Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T.; Arnulf, B.; Cavo, M.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save